Guided Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,179.00
823.00
606.00
605.00
244.00
57
Cost of Goods Sold (COGS) incl. D&A
1,072.00
1,374.00
1,591.00
1,716.00
743.00
116
Gross Income
107.00
551.00
985.00
1,111.00
499.00
59
SG&A Expense
6,713.00
8,118.00
5,242.00
2,709.00
2,622.00
1,489
EBIT
6,606.00
8,669.00
-
3,820.00
3,121.00
1,548
Unusual Expense
674.00
260.00
568.00
1,677.00
6,487.00
4,273
Non Operating Income/Expense
110.00
25.00
74.00
68.00
18.00
54
Interest Expense
45.00
979.00
1,317.00
1,895.00
1,106.00
1,763
Pretax Income
7,215.00
9,883.00
6,902.00
3,970.00
10,696.00
1,016
Consolidated Net Income
7,215.00
9,883.00
6,902.00
3,970.00
10,696.00
1,016
Net Income
7,215.00
9,883.00
6,902.00
3,970.00
10,696.00
1,016
Net Income After Extraordinaries
7,215.00
9,883.00
6,902.00
3,970.00
10,696.00
1,016
Net Income Available to Common
10,390.00
10,035.00
9,503.00
4,995.00
10,974.00
900
EPS (Basic)
12,616.11
10,417.72
593,937.60
24.61
1.29
0.02
Basic Shares Outstanding
0.80
1.00
0.00
203.00
8,479.00
462
EPS (Diluted)
12,616.11
10,417.72
475,150.00
24.61
1.29
0.01
Diluted Shares Outstanding
0.80
1.00
0.00
203.00
8,479.00
65,227
EBITDA
6,145.00
8,186.00
5,173.00
2,597.00
2,908.00
1,521
Preferred Dividends
3,175.00
152.00
2,601.00
1,025.00
278.00
116
About Guided Therapeutics
View Profile
